| Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 GA Rouleau, P Merel, M Lutchman, M Sanson, J Zucman, C Marineau, ... Nature 363 (6429), 515-521, 1993 | 1656 | 1993 |
| Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas M Sanson, Y Marie, S Paris, A Idbaih, J Laffaire, F Ducray, S El Hallani, ... J Clin Oncol 27 (25), 4150-4154, 2009 | 1171 | 2009 |
| Genome-wide association study identifies five susceptibility loci for glioma S Shete, FJ Hosking, LB Robertson, SE Dobbins, M Sanson, B Malmer, ... Nature genetics 41 (8), 899-904, 2009 | 886 | 2009 |
| Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and … MJ van den Bent, AF Carpentier, AA Brandes, M Sanson, MJB Taphoorn, ... Journal of Clinical Oncology 24 (18), 2715-2722, 2006 | 854 | 2006 |
| Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113, 2020 | 689 | 2020 |
| Clinical trial of blood-brain barrier disruption by pulsed ultrasound A Carpentier, M Canney, A Vignot, V Reina, K Beccaria, C Horodyckid, ... Science translational medicine 8 (343), 343re2-343re2, 2016 | 641 | 2016 |
| MGMT testing—the challenges for biomarker-based glioma treatment W Wick, M Weller, M Van Den Bent, M Sanson, M Weiler, A Von Deimling, ... Nature Reviews Neurology 10 (7), 372-385, 2014 | 583 | 2014 |
| IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas C Houillier, X Wang, G Kaloshi, K Mokhtari, R Guillevin, J Laffaire, S Paris, ... Neurology 75 (17), 1560-1566, 2010 | 581 | 2010 |
| IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for … MJ Van den Bent, HJ Dubbink, Y Marie, AA Brandes, MJB Taphoorn, ... Clinical Cancer Research 16 (5), 1597-1604, 2010 | 478 | 2010 |
| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 445 | 2020 |
| A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry S El Hallani, B Boisselier, F Peglion, A Rousseau, C Colin, A Idbaih, ... Brain 133 (4), 973-982, 2010 | 420 | 2010 |
| Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions K Hoang-Xuan, L Capelle, M Kujas, S Taillibert, H Duffau, J Lejeune, ... Journal of clinical oncology 22 (15), 3133-3138, 2004 | 411 | 2004 |
| Glioblastoma targeted therapy: updated approaches from recent biological insights M Touat, A Idbaih, M Sanson, KL Ligon Annals of Oncology 28 (7), 1457-1472, 2017 | 394 | 2017 |
| Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3 … MJ van den Bent, B Baumert, SC Erridge, MA Vogelbaum, AK Nowak, ... The Lancet 390 (10103), 1645-1653, 2017 | 364 | 2017 |
| Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome G Kaloshi, A Benouaich-Amiel, F Diakite, S Taillibert, J Lejeune, ... Neurology 68 (21), 1831-1836, 2007 | 343 | 2007 |
| Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle … C Soussain, K Hoang-Xuan, L Taillandier, E Fourme, S Choquet, F Witz, ... Journal of clinical oncology 26 (15), 2512-2518, 2008 | 329 | 2008 |
| Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1) A retrospective study of 104 patients JS Guillamo, A Creange, C Kalifa, J Grill, D Rodriguez, F Doz, S Barbarot, ... Brain 126 (1), 152-160, 2002 | 324 | 2002 |
| All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 M Labussiere, A Idbaih, XW Wang, Y Marie, B Boisselier, C Falet, S Paris, ... Neurology 74 (23), 1886-1890, 2010 | 319 | 2010 |
| Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors BS Melin, JS Barnholtz-Sloan, MR Wrensch, C Johansen, D Il'Yasova, ... Nature genetics 49 (5), 789-794, 2017 | 315 | 2017 |
| MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group … MJ van den Bent, HJ Dubbink, M Sanson, CR van der Lee-Haarloo, ... Journal of Clinical Oncology 27 (35), 5881, 2009 | 299 | 2009 |
